THERAPEUTIC COMBINATION OF A CD19 INHIBITOR AND A BTK INHIBITOR

Abstract

Therapeutic combinations of a CD19 inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention relates to pharmaceutical compositions comprising combinations of a CD19 inhibitor and a BTK inhibitor, as well as methods for using the pharmaceutical compositions to treat a disease, particularly a cancer, such as a hematological malignancy. The invention also relates to a combination of a BTK inhibitor and a CD19 inhibitor, such as a CD19-targeting antibody or a CD19-targeting chimeric antigen receptor, expressing a T lymphocyte or an NK cell, and its compositions and uses. Combinations of a btk inhibitor and a cd 19 inhibitor with a programmed inhibitor of death-1 (pd-1) or pd-1 (pd-l1) and their compositions and uses are also described.